Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest update is out from ANGLE plc ( (GB:AGL) ).
ANGLE plc reported a 31% increase in revenue for 2024, driven by its strategic focus on large pharmaceutical contracts, despite challenges in product sales due to regulatory changes and reduced research funding. The company has streamlined operations and secured multiple agreements with major pharma companies, positioning itself for sustainable growth and future collaborations. ANGLE’s advancements in next-generation sequencing assays and its pivotal role in groundbreaking cancer research highlight its potential impact on the industry. While the company anticipates modest revenue growth in 2025, it remains optimistic about converting ongoing discussions into substantial opportunities.
The most recent analyst rating on (GB:AGL) stock is a Buy with a £70.00 price target. To see the full list of analyst forecasts on ANGLE plc stock, see the GB:AGL Stock Forecast page.
More about ANGLE plc
ANGLE plc is a leading company in the liquid biopsy industry, specializing in circulating tumor cell (CTC) solutions for research, drug development, and clinical oncology. The company focuses on innovative technologies for cancer diagnostics and has established significant partnerships with large pharmaceutical companies to enhance drug discovery and development.
Average Trading Volume: 1,093,524
Technical Sentiment Signal: Sell
Current Market Cap: £33.86M
See more insights into AGL stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue